Evommune, INC Form 4 insider transactions

Evommune, Inc. Chief Financial Officer Kyle Carver reported a transaction involving the purchase of 1,000 shares of common stock.

Director Arthur Kirsch acquired 10,000 shares of Evommune, Inc. common stock for $13.30 per share on July 7, 2026.

Evommune, Inc. reports Janice Suzann Drew's transactions of common stock and employee stock options under a pre-arranged trading plan.

Evommune, Inc. reports insider transactions by Chief Scientific Officer Jeegar Pravinkumar Patel, involving stock options and common stock under a Rule 10b5-1 trading plan.

Evommune, Inc. President & CEO Luis C. Pena reported the sale of 7,438 shares of common stock for $22.71 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Benjamin F. McGraw III was granted 15,673 stock options in Evommune, Inc. as part of standard equity compensation.

Director Arthur S. Kirsch was granted 15,673 stock options in Evommune, Inc. as part of standard equity compensation.

Director David E. Cohen sold 6,056 shares of Evommune, Inc. common stock and received a new stock option grant.

Chief Scientific Officer Jeegar Patel exercised options for 13,512 shares and sold 16,687 shares of Evommune, Inc. common stock.

Evommune, Inc. President and CEO Luis C. Pena sold 16,787 shares of common stock pursuant to a pre-arranged Rule 10b5-1 trading plan.

Chief Business & Legal Officer Gregory S. Moss exercised options and sold 14,223 shares of Evommune, Inc. common stock.

Evommune CFO Kyle Carver exercised 15,000 stock options and sold 18,175 shares of common stock under a 10b5-1 trading plan.

Evommune, Inc. Chief Scientific Officer Jeegar Patel was granted 69,315 employee stock options on April 16, 2026.

Chief of Development Operations Janice Suzann Drew was granted 73,892 stock options in Evommune, Inc.

Evommune, Inc. Chief Medical Officer Eugene Bauer was granted 51,117 employee stock options with an exercise price of $26.77.

Evommune, Inc. Chief Financial Officer Kyle Carver was granted 98,946 employee stock options with an exercise price of $26.77.

Chief Business & Legal Officer Gregory S. Moss was granted 115,279 stock options in Evommune, Inc.

Evommune, Inc. President and CEO Luis C. Pena was granted 291,420 employee stock options with an exercise price of $26.77.

LSP 7 Cooperative UA, a 10% owner and director, acquired 358,680 shares of Evommune, Inc. common stock for $27.88 per share.

Evommune Director Felice Isabel Verduyn-van Weegen reported a planned acquisition of 358,680 common shares at $27.88 per share, effective February 17, 2026.